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Few studies, based on a limited number of patients using non-uniform therapeutic protocols,
have analyzed Methicillin-resistant Staphylococcus aureus (MRSA) eradication.
Methods
In a randomized multicenter trial conducted on patients with new-onset MRSA infection we
evaluated the efficacy of an early eradication treatment (arm A) compared with an observa-
tional group (B). Arm A received oral rifampicin and trimethoprim/sulfamethoxazole (21
days). Patients’ microbiological status, FEV1, BMI, pulmonary exacerbations and use of
antibiotics were assessed.
Results
Sixty-one patients were randomized. Twenty-nine (47.5%) patients were assigned to active
arm A and 32 (52.5%) patients to observational arm B. Twenty-nine (47.5%) patients, 10
patients in arm A and 19 in arm B, dropped out of the study. At 6 months MRSA was eradi-
cated in 12 (63.2%) out of 19 patients in arm A while spontaneous clearance was observed
in 5 (38.5%) out of 13 patients in arm B. A per-protocol analysis showed a 24.7% difference
in the proportion of MRSA clearance between the two groups (z = 1.37, P(Z>z) = 0.08).
Twenty-seven patients, 15 (78.9%) out of 19 in arm A and 12 (92.3%) out of 13 in arm B,
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were able to perform spirometry. The mean (±SD) FEV1 change from baseline was 7.13%
(±14.92) in arm A and -1.16% (±5.25) in arm B (p = 0.08). In the same period the BMI
change (mean ±SD) from baseline was 0.54 (±1.33) kg/m2 in arm A and -0.38 (±1.56) kg/m2
in arm B (p = 0.08). At 6 months no statistically significant differences regarding the number
of pulmonary exacerbations, days spent in hospital and use of antibiotics were observed
between the two arms.
Conclusions
Although the statistical power of the study is limited, we found a 24.7% higher clearance of
MRSA in the active arm than in the observational arm at 6 months. Patients in the active
arm A also had favorable FEV1 and BMI tendencies.
Introduction
Pulmonary infection is the principal characteristic of cystic fibrosis (CF) and the main cause of
morbidity and mortality [1–4]. The major pathogens responsible for respiratory tract infec-
tions in CF patients are Staphylococcus aureus and Pseudomonas aeruginosa [1,2]. Methicillin-
resistant Staphylococcus aureus (MRSA) infection is a matter of concern since persistent infec-
tion due to this bacterium is associated with an increased rate of decline in lung function and
higher mortality [2–4].
Only a limited number of studies have analyzed the pros and cons of early MRSA eradica-
tion, and all reported experiences are based on a limited number of patients, on the use of
non-uniform therapeutic protocols and on heterogeneous topical decolonization practices [5–
10]. Furthermore, the definitions of eradication used for MRSA infection do not fully satisfy
the definition of eradication used in clinical practice for other pathogens such as P. aeruginosa,
which is usually based on 3 negative cultures in a 6-month period [11–13]. Moreover, the
long-term risk of the emergence of new pathogens due to treatment has only been partly evalu-
ated. In the absence of a gold standard treatment for new-onset MRSA infection [5–10], we
hypothesized that an early eradication protocol enacted at the time of a first or new MRSA
infection is a more effective way to clear this pathogen in comparison to observation alone.
Aims of the study
The primary aim of this open-label, randomized, multicenter, parallel-group study was to eval-
uate, on a sample of clinically stable CF patients, the efficacy of an eradication protocol against
new-onset MRSA infection in comparison to observation alone.
The secondary aims of this study were:
1. to assess the change in forced expiratory volume in one second (FEV1) and body mass
index (BMI) in patients in the active arm (A) and in the observation arm (B) during a time
span of 6 months;
2. to determine the existence of any differences between the 2 arms in regard to the period in
which the patient remains MRSA-free;
3. to determine if the eradication treatment is associated with an increasing risk of emergence
of particular pathogens (Burkholderia cepacia complex and other non-fermentative Gram-
negative bacteria) in the respiratory tract;
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4. to assess the number of pulmonary exacerbations and hospitalizations, the days of total
(oral, inhaled and intravenous) antibiotic usage, in the 2 arms during a time span of 6
months;
5. to evaluate the antibiotic susceptibility and molecular characteristics of MRSA strains iso-
lated from the airways of CF patients experiencing new-onset MRSA infection.
Materials and methods
Centers
Five CF Referral Centers (Florence, Rome, Milan, Messina and Naples), established by Italian
law [14], participated in this trial. The study received ethical approval from the Ethics Com-
mittees of Meyer Hospital (Florence), Institute Bambino Gesu` (Rome), Milan, Messina and
Naples and written patient consent was obtained. The trial was registered as Eudract (EU Clin-
ical Trials Register) number 2013-000219-25.
Participants
Patients in regular clinical and microbiological follow-up [15] were considered eligible if more
than 4 years old and experiencing new-onset MRSA infection. New-onset MRSA infection was
considered baseline and was defined as either a first isolation of MRSA from the airways of the
CF patient or a new MRSA isolation after a clearance period of 12 months (after performance
of 4 negative cultures).
CF diagnosis was based on clinical features of the disease,� 60 mmol/L concentration of
chloride in sweat and/or the presence of two CF-causing mutations [16].
Patients were excluded from the study on the basis of the following criteria:
• Respiratory exacerbation [17] at the time of randomization
• History of hypersensitivity to or adverse reaction to antibiotics used in the intervention of
the study.
• Liver cirrhosis or abnormal liver function test results at study entry (defined as ALT and/or
AST levels more than twice the upper limit of the normal range)
• Abnormal kidney function at study entry (defined as a serum creatinine level >1.5 times the
upper limit normal for the participant’s age)
• Pregnancy
• Lung/liver transplantation
• Contemporaneous use of any investigational drug
• MRSA resistance to both antibiotics, trimethoprim/sulfamethoxazole (TMP/SMX) and
rifampicin
Written informed consent was obtained from all participants in the study. Parents gave
their consent for minors.
Randomization
Between July 18th, 2013, and April 12th, 2016, 61 CF patients with a first/new MRSA infection
were randomly assigned to the active arm (A) or observational arm (B). A balanced randomi-
zation sequence with permuted blocks of size 4 was created using statistical software.
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Randomization assignment, performed at the coordinator Center (Meyer Hospital), was orga-
nized by e-mail. Patients, allocated 1:1, were enrolled at their own CF Center. The people
involved in randomization and in the treatment assignments were kept completely separate
[18].
Procedures
Patients randomized to the active arm (A) were treated with the following antibiotic regimen:
• Oral rifampicin 15 mg/kg/day in 2 daily doses (maximum daily dose 600 mg) for 21 days
• Oral TMP-SMX 8–40 mg/kg/day in 2 daily doses (maximum daily dose 320/1600 mg) for 21
days
• 2% nasal mupirocin–each nostril 3 times daily for 5 days
In case of antibiotic resistance, an alternative approach was planned: patients over 8 years
of age were treated with rifampicin and minocycline when MRSA was resistant to TMP/SMX,
or with TMP/SMX and minocycline (pediatric dose: 2 mg/kg orally twice daily for 21 days,
adult dose: 100 mg orally twice daily for 21 days) when MRSA was resistant to rifampicin.
Physicians of the respective Centers managed the patients’ clinical course according to stan-
dards of care [15]. Treatment was suspended in cases of adverse effects or pulmonary exacer-
bation [17].
Treatment costs were covered by the Italian National Health Service at no charge to the
patients [14]. FEV1 values were measured according to ATS-ERS standards [19].
Patients’ microbiological status was determined according to the European CF Registry def-
initions at the time of new-onset MRSA infection [1].
Microbiological analyses were performed following published literature. Antibiotic suscep-
tibility was evaluated using the VITEK2 (bioMe´rieux) automated system and EUCAST clinical
breakpoints were used as interpretation criteria [www.eucast.org/clinical_breakpoints/]. DNA
extractions were performed for each isolate. To determine the potential virulence of MRSA
strains, a specific PCR assay for the presence of the Panton-Valentine Leukocidin (PVL) gene
was performed [20]. The mecA gene and other loci of the SCCmec cassette were analyzed using
different multiplex PCR [21].
Sequence typing and spa-typing were performed by whole genome sequencing and ana-
lyzed using MetaMLST [22] and the DNAGear software [23] respectively.
Outcomes
The primary outcome was MRSA eradication, defined as the patient having 3 successive nega-
tive cultures in 6 months according to the United Kingdom CF Trust criteria [24]. During this
same 6-month period, we also assessed the patients’ FEV1 change, nutritional status (BMI),
pulmonary exacerbations and antibiotic use. Having received antibiotics potentially active
against MRSA during the follow-up was considered a cause of drop-out.
Results of cultures and clinical records were used to assess secondary aims.
Statistical analyses
This trial was designed by calculating the sample size as a balance between statistical consider-
ations [18] and epidemiological experience of MRSA infection in Italy [25]. We hypothesized
that MRSA eradication would occur in 75% of cases in the active arm and spontaneous clear-
ance in 50% of the observation group. Using a one-tailed test (which means that only an effect
in the expected direction is interpreted), and having set the alpha (type I) error at 0.05 and the
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beta (type II) error at 30%, we planned to enroll 60 patients (30 per arm) in a 2-year trial to
reach statistical significance. A 25% greater rate of eradication in arm A in comparison with
arm B was considered clinically relevant. Data were independent, with one observation per
participant [18].
The results of the study were reviewed and evaluated by the Data Safety Monitoring Board.
Since recruitment was behind schedule, this Board agreed on an extension of the recruitment
period by one year in all the participating Centers. The necessity of administering antibiotics
during the 6-month follow-up period (in order to satisfy the definition of eradication) led us
to perform a per-protocol analysis because an intention-to-treat analysis would not have pro-
vided an appropriate interpretation of the data [18]. The primary outcome was evaluated using
a two sample test of proportion. The percentage of MRSA free patients was assessed during the
follow-up at 60, 120 and 180 days; 95% confidence intervals (CI) were calculated using exact
likelihood ratios.
Regarding secondary aims, quantitative variables were expressed as mean ± SD. The differ-
ences between the 2 arms regarding continuous variables were assessed using Student’s t-test.
Level of significance was set to 5%, two-tailed, when not otherwise specified.
We conducted all statistical analyses using STATA version 13.0 (StataCorp.2013. Stata Sta-
tistical Software: Release 13. College Station, TX: StataCorp LP).
Results
Fig 1 shows the trial profile. Sixty-eight patients were assessed for eligibility from February 1,
2013 to April 30, 2016. Sixty-one (89.7%) patients were randomized with 29 (47.5%) patients
being assigned to arm A and 32 (52.5%) to arm B.
The oral rifampicin/TMP-SMX protocol was used in 25 (86.2%) out of 29 patients in the
active arm, and an alternative approach was used in 4 (13.8%) patients (2 patients were treated
with both TMP-SMX/minocycline due to rifampicin resistance and 2 others with both rifam-
picin/minocycline due to suspected TMP-SMX allergy or side effects). The time (mean ± SD)
from new-onset MRSA infection diagnosis to the time of treatment initiation was 27 ± 32
days.
Twenty-nine (47.5%) out of 61 randomized patients, 10 patients in arm A and 19 in arm B,
dropped out of the study. Causes of drop-out are shown in Fig 1. The main cause of drop-out
was the administration of further antibiotic treatment due to variations in the patient’s clinical
condition during follow-up in 4 (40%) out of 10 patients in arm A and 12 (63.2%) out of 19 in
arm B.
Table 1 shows patients’ clinical characteristics.
Fifty-two (85.2%) out of 61 participants, 24 patients in arm A and 28 in arm B, were able to
perform spirometry (�5 years of age).
MRSA was firstly isolated in 55 (90.2%) out of 61 patients included in this trial, 26 (89.7%)
in arm A and 29 (90.6%) in arm B, while MRSA was previously isolated in 6 (9.8%) patients, 3
(10.3%) in arm A and 3 (9.4%) in arm B. No statistically significant difference in first and pre-
viously MRSA infected patients was observed between the 2 arms (p = 1). In those patients
who had previous MRSA infection the mean (±SD) time from the previous isolation was 741
±506.89 days in arm A and 1630±1265.40 days in arm B (p = 0.32).
Microbiological cultures were performed on specimens collected by throat swabs in 12
(19.7%) out of 61 patients, 7 (24.1%) out of 29 patients in arm A and 5 (15.6%) out of 32
patients in arm B (Table 1). Sputum cultures were performed in 49 (80.3%) patients, 22
(75.9%) out of 29 patients in arm A and 27 (84.4%) out of 32 patients in arm B. No statistically
significant difference regarding sampling methods was observed between the 2 arms (p = 0.6).
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No substantial differences regarding chronic/intermittent co-infections with other causa-
tive pathogens were observed between the groups.
Five patients from whom Aspergillus was isolated did not fulfil criteria for allergic broncho-
pulmonary aspergillosis and no patients were on treatment with oral steroids [26]. The 2
Fig 1. Trial profile.
https://doi.org/10.1371/journal.pone.0213497.g001
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Table 1. Patients’ characteristics.
Arm A
(active arm)
Arm B (observational arm)









Male 20 (69.0%) 15 (46.9%)
Female 9 (31.0%) 17 (53.1%)
CFTR genotype
F508del homozygotes 7 (24.1%) 6 (18.8%)
F508del heterozygotes 13 (44.9%) 16 (50.0%)
Other genotype 9 (31.0%) 10 (31.2%)
Anthropometrics (mean ± SD)
Weight (kgs) 45.15 ± 21.85 41.84 ± 20.09
Height (cm) 146.64 ± 27.02 142.95 ± 26.48
BMI (Kg/m2) 19.18 ± 3.92 18.75 ± 4.11
Spirometry
FEV1 (L) 2.20 ± 0.97 2.05 ± 0.87
FEV1 (% of predicted) 78.13 ± 24.70 81.95 ± 27.31
FEV1 groups
� 70 16 (55.2%) 21 (65.6%)
< 70 8 (27.6%) 7 (21.9%)
Unable to perform spirometry 5 (17.2%) 4 (12.5%)
First MRSA infection 26 (89.7%) 29 (90.6%)
Previously infected 3 (10.3%) 3 (9.4%)
Sampling methods
Throat swabs 7 (24.1%) 5 (15.6%)
Sputum 22 (75.9%) 27 (84.4%)
Patients’ microbiological status for other pathogens at baseline
Methicillin-sensitive Staphylococcus aureus (MSSA)
Positive 10 (34.5%) 12 (37.5%)
Negative 19 (65.5%) 20 (62.5%)
P. aeruginosa
Positive [chronic] 12 (41.4%) [6] 17 (53.1%) [4]
Negative 17 (58.6%) 15 (46.9%)
A. xylosoxidans
Positive 1 (3.4%) 1 (3.1%)
Negative 28 (96.6%) 31 (96.9%)
S. maltophilia
Positive 1 (3.4%) 4 (12.5%)
Negative 28 (96.6%) 28 (87.5%)
Aspergillus spp
Positive 0 (0%) 5 (15.6%)
Negative 29 (100%) 27 (84.4%)
Other
6 (20.7%) 11 (34.4%)
4 with H. influenzae 9 with H. influenzae
2 with B. gladioli 2 with nontuberculous mycobacteria
https://doi.org/10.1371/journal.pone.0213497.t001
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patients from whom nontuberculous mycobacteria were isolated did not fulfil criteria for non-
tuberculous mycobacterial lung disease [27].
Primary endpoint: MRSA eradication
The per-protocol analysis indicated that MRSA was eradicated in 12 (63.2%) out of 19 patients
in arm A while spontaneous clearance was observed in 5 (38.5%) out of 13 patients in arm B.
There was a 24.7% (z = 1.37, P(Z>z) = 0.08, one-tailed) difference in MRSA clearance between
the two groups.
In arm A 11 (91.7%) out of 12 patients in whom MRSA was eradicated had a first infection
and only 1 patient was previously infected.
Two patients in arm A stopped treatment due to untoward effects which were probably
attributable to the therapy (1 patient with vomiting and another with urticaria), although the
severity of the effects did not require hospitalization.
Secondary endpoints
1. FEV1 and BMI change. At 6 months following the treatment period, the mean (±SD)
absolute change in FEV1 (percentage of predicted) from baseline was 7.13% (±14.92) in 15
patients able to perform spirometry in arm A and -1.16% (±5.25) in 12 patients able to perform
spirometry in arm B (p = 0.08). In the same period the BMI change (mean ±SD) from baseline
was 0.54 (±1.33) kg/m2 in 19 patients in arm A and -0.38 (±1.56) kg/m2 in 13 patients in arm B
(p = 0.08).
2. MRSA-free period. Table 2 illustrates the percentage of MRSA-free patients for each of
the three cultures in both arms of the study over 6 months. The limited number of patients in
the study entails a degree of uncertainty regarding this estimation with overlapping confidence
intervals.
3. Microbiological status of patients at six months. As shown in Table 3, after assess-
ment of the microbiological status of patients at 6 months, we observed an increase in patients
infected by S. aureus (MSSA) in both arms of the study. No substantial change in the preva-
lence of P. aeruginosa, A. xylosoxidans and S. maltophilia infections was observed. No B. cepa-
cia complex was isolated from patients in either arm of the study.
4. Pulmonary exacerbations and use of antibiotics. During the time of the study 6
(31.6%) out of 19 patients in arm A and 4 (30.8%) out of 13 patients in arm B were treated
with intravenous antibiotics. No statistically significant difference was observed in the number
of patients treated intravenously between the 2 arms of the study (p = 1). Pulmonary exacerba-
tions [17], hospitalizations and days of total (oral, inhaled and intravenous) antibiotic usage
were assessed in the active and observational arms for 6 months (Table 4). We found no statis-
tically significant differences between patients in arm A and arm B.
5. Microbiological data. The susceptibility pattern of all MRSA strains at baseline is
shown in Table 5. Molecular analysis was performed on the 18 (29.5%) out of 61 MRSA iso-
lates which arrived at the Central laboratory. The distribution of SCCmec types, PVL produc-
tion, spa types and ST among patients are described in Table 6. The most frequent clones were
ST22-IV (27.8%) and ST1-IV (16.6%) and the most represented SCCmec types were type IV
(67%), followed by types V and I (11%) and type III (5%) [20,21]. Only 2 isolates were positive
for the PVL gene.
Discussion
The present study was designed to evaluate the efficacy of an early eradication treatment pro-
tocol lasting 21 days against new-onset MRSA infection in CF patients in various centers
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around Italy, where the prevalence of this pathogen is only partially known [1, 25]. Over a 6-
month period, we observed a 24.7% difference in MRSA clearance between patients in the
active arm A and observational arm B of the study, according to per-protocol statistical analy-
sis. During the same period, we also saw positive effects in respiratory function (FEV1), nutri-
tional status (BMI) and MRSA-free period in the patients of the active arm. The
microbiological analysis of patients provided indications of sensitivity to the antibiotics and
molecular characteristics of a subset of MRSA strains responsible for the new-onset infection.
The principal limitations of the present study are the limited statistical power, the high
drop-out number and the per-protocol analysis, that could overestimate the effectiveness of
Table 2. MRSA-free patients at 1st, 2nd, and 3rd culture for treatment and observational arm. Percentage of MRSA-free patients and 95% CI calculated using exact
likelihood.
Enrolled Patients MRSA-free Patients Patients with MRSA isolation Percentage of MRSA-free patients
n n n (95% CI)
Arm A (29 patients)
Drop-out 10
Completed follow-up 19
at 1st culture (60 days) 14 5 74 (49–91)
at 2nd culture (120 days) 13 6 68 (43–87)
at 3rd culture (180 days) 12 7 63 (38–84)
Arm B (32 patients)
Drop-out 19
Completed follow-up 13
at 1st culture (60 days) 7 6 54 (25–81)
at 2nd culture (120 days) 6 7 46 (19–75)
at 3rd culture (180 days) 5 8 38 (14–68)
https://doi.org/10.1371/journal.pone.0213497.t002
Table 3. Co-infection with other pathogens at 6 months.
Arm A Arm B
Number of patients n = 19 n = 13
S. aureus (MSSA)
Positive 11 (57.9%) 8 (61.5%)
Negative 8 (42.1%) 5 (38.5%)
P. aeruginosa
Positive [chronic] 4 (21.1%) [4] 5 (38.5%) [4]
Negative 15 (78.9%) 8 (61.5%)
A. xylosoxidans
Positive 1 (5.3%) 0 (0%)
Negative 18 (94.7%) 13 (100%)
S. maltophilia
Positive 1 (5.3%) 4 (30.8%)
Negative 18 (94.7%) 9 (69.2%)
Aspergillus spp
Positive 0 (0%) 3 (23.1%)
Negative 19 (100%) 10 (76.9%)
Other
Positive 5 (26.3%)
2 with B. gladioli
3 with H. influenzae
2 (15.4%)
1 with nontuberculous mycobacterium
1 with H. influenzae
https://doi.org/10.1371/journal.pone.0213497.t003
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the intervention [18]. Despite these limits, our study helps to gain experience in the treatment
of new-onset MRSA infection in CF and gives credence to the idea that early intervention
could increase the clearance of this pathogen. The slow recruitment of patients to this study
was due to overestimation of the incidence of MRSA infection in Italy, while designing the
trial [25]. The epidemiology of this infection is not currently defined by the European CF Soci-
ety Registry [1] and can vary notably from place to place.
Antibiotics potentially active against MRSA are sometimes used in CF patients co-infected
with other pathogens. In both study arms the high drop-out percentage can be attributed to
the need to administer additional antibiotics against MRSA due to worsening clinical condi-
tions or to the use of other antibiotics to treat P. aeruginosa infection [28]. Although tobramy-
cin and quinolones are not usually prescribed to treat MRSA infections [24,29], we consider
the use of such drugs as a reason for drop-out given that their activity against MRSA cannot be
excluded [24, 25, 30, 31].
Table 4. Pulmonary exacerbations, days spent in hospital and antibiotic use over 6 months of study.
Arm A (19 patients) Arm B (13 patients) p value Difference
(95% CI)
Exacerbations (number) 1.00±0.82 0.85±1.07 0.66 0.15
(-0.53 to 0.83)
Days spent in hospital (mean±SD) 4.26±6.16 3.62±6.56 0.78 0.64
(-4.01 to 5.29)
Intravenous treatment (days) (mean±SD) 6.37±9.77 6.38±10.67 0.99 0.01
(-7.46 to 7.44)
Oral treatmenta (days) (mean±SD) 39.47±32.95 41.08±45.84 0.91 -1.61
(-30.00 to 26.78)
Inhalation treatment (days) (mean±SD) 44.47±64.12 47.77±43.37 0.87 -3.33
(-45.01 to 38.41)
a including azithromycin treatment
https://doi.org/10.1371/journal.pone.0213497.t004
Table 5. Percentage of susceptibility of 61 MRSA strains at baseline.
Antimicrobial %
Sensitive Intermediate Resistant
Clindamycin 1 38 0 62
Daptomycin 98 0 2
Tigecycline 98 0 2
TMP/SMX 98 0 2
Linezolid 93.9 0 6.1
Rifampicin 92 0 8
Mupirocin 92 6 2
Fusidic acid 86.3 0 13.7
Moxifloxacin 64.3 28.6 7.1
Teicoplanin 100 0 0
Vancomycin 100 0 0
Tetracycline 64 4 32
Gentamicin 61.8 2.9 35.3
Levofloxacin 56.9 1.9 41.2
1 Clindamycin is reported as total resistance (constitutive plus inducible).
https://doi.org/10.1371/journal.pone.0213497.t005
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The difference in MRSA clearance between the 2 arms of the study confirms previous
observations [5–10] regarding the microbiological efficacy of the treatment and reinforces the
idea of eradicating this pathogen during its initial phases of infection. It can be hypothesized
that early treatment can clear the pathogen before it has a chance to adapt to the respiratory
tract of the CF patient, as seen with P. aeruginosa [32, 33].
In our study, treatment was started quickly and the average time between new-onset MRSA
infection diagnosis and the time of treatment initiation was in accordance with the times in
the best practice guidelines against P. aeruginosa [15]. Moreover, the measure outcome was
based on three microbiological cultures carried out over a period of 6 months, thereby comply-
ing with the definitions normally used in clinical practice to describe the efficacy of eradicating
treatment [11,13, 24]. The definition of eradication used in other experiences, based on a single
culture or on limited observation period fails to satisfy the definition of eradication normally
used for other pathogens [5, 6, 8, 10].
The phenomenon of spontaneous clearance of the pathogen has been described for some
time, and we observed a proportion in our observational arm analogous to that found in other
studies [5–10]. The explanation for this phenomenon is currently unknown.
Although we were unable to enroll as many participating patients as we intended, our
results should be evaluated from a clinical point of view. A difference of 24.7% in pathogen
clearance between the active and the observational arm is an important difference.
The possibility of eradicating MRSA in the initial phases of infection, [5–10], the consider-
able worsening of clinical conditions due to persistent MRSA infection [3,4] and other obser-
vations, such as the consistently unfavorable effect on the course of the disease when the
patient has MRSA and P. aeruginosa co-infection [34,35], should reinforce the decision to
intervene rapidly. Our experience, together with results from previous studies, could contrib-
ute to proposals which include early MRSA eradication treatment as part of the standard of
care of CF patients.
Our results can be generalized clinically. We respected the definitions of eradication which
are also valid for other pathogens and considered proper clinical practice [11–13]. We enrolled
a group of patients with variable characteristics of age, sex and disease severity. The mean age
of our patients was analogous to the age of other subjects infected by MRSA [2]. We cannot
exclude the possibility that patients even younger than ours are infected by MRSA strains, but
in these cases, treatment efficacy remains to be demonstrated.
Our microbiological analysis performed on a subset of strains responsible for the infection
in our study population indicates that they were mainly community-acquired MRSA
(CA-MRSA). This observation brings up the problem of environmental and skin
Table 6. The distribution of SCCmec types, PVL status and Sequence Types (ST) on 18 (29.5%) out of 61 MRSA isolates.
Clone name ST SCCmec spa type PVL Patients N.
ST1-IV 1 IV t127/n.id. negative 3
ST1-V 1 V t127 negative 1
ST5-III 5 III t002 negative 1
ST8-IV 8 IV t008 negative 1
ST15-I 15 I n.id. negative 1
ST22-IV 22 IV t852/t1977 1 positive 5
ST59-V 59 V t216 negative 1
ST97-IV 97 IV t359 negative 1
ST398 398 n.id. t108 negative 1
n.id. n.id. I (1)/IV(2) t019/n.id. 1 positive 3
https://doi.org/10.1371/journal.pone.0213497.t006
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decontamination [11]. Cutaneous and/or environmental decontamination might be somewhat
difficult [10,11,36–38] as patients may not easily accept this practice on a daily basis. Our pro-
tocol, involving use of only one hygienic measure aimed at reducing nasal colonization, (rather
than cutaneous and environmental decontamination), was probably easier for the patient to
accept and simpler to carry out than other previous experiences [10]. The assessment of the
efficacy of the different practices of environmental, nasal and skin decontamination in reduc-
ing over time the phenomenon of MRSA pulmonary re-colonization needs further studies.
The results from our study seem to indicate that the risk of acquiring an infection due to
other non-fermenter Gram negatives pathogens was not consistent. During the study, in both
arms, we observed an increase in MSSA co-infection at 6 months. The reasons and the clinical
significance of this phenomenon are not known. The strategies adopted by the Centers partici-
pating in the study regarding the MSSA infection were not investigated. Unlike P. aeruginosa
strategies, where there is universal consensus regarding the approach [15], there is no agree-
ment regarding MSSA infection [39]. Furthermore, the follow-up period of the present study
did not allow us to ascertain whether the MSSA increase was transitory or persistent. [1,15].
The eradication protocol that we chose to evaluate in this trial is based on patterns of sensi-
tivity of the MRSA isolates in Italy [25], on the cost of the pharmaceuticals used, and the fact
that some drugs which are active against MRSA, such as fusidic acid, are not currently avail-
able in Italy. The drugs which should be used in an early-eradication protocol of MRSA obvi-
ously need to be selected on the basis of antibiotic-susceptibility of the strains responsible for
the new-onset infection, which are often resistant to various drugs [24,29, 40]. This fact means
that it is not possible to recommend a gold standard since physicians must often select alterna-
tive protocols based on the resistance patterns of the local strains affecting their patients. Due
to the limited experience in the field of MRSA eradication in CF, other studies are definitively
necessary. Large-scale studies designed to compare the clinical efficacy of various types of
treatments are theoretically feasible [41] but the growing number of patients involved in clini-
cal trials may make it difficult to recruit the number of subjects necessary to reach statistical
power. Moreover, running clinical trials on MRSA new infection is made more difficult
because of absence of data on MRSA prevalence in certain countries, the need to treat patients
with antibiotics potentially active against MRSA and the lack of a universally accepted defini-
tion of eradication.
In our study, the antibiotics have been well tested in the clinic and do not pose a significant
risk of side effects. Although individual allergic reactions in patients cannot be excluded, the
classes of antibiotics which are effective against MRSA are less allergenic than other classes
(such as the beta-lactams) [42]. We cannot exclude the possibility that antibiotics by aerosol
inhalation are used in the early phases of the infection. Clinical trials on the use of vancomycin
against persistent MRSA infection are ongoing [43].
In conclusion, the results of our study agree with previous experiences regarding the possi-
bility of eradicating new-onset MRSA infection [5–10], and show favorable effects in CF
patients’ FEV1 and BMI over a period of 6 months. These results, together with other data
from the literature and the low risk of side effects of the treatment, suggest that this strategy
could be more widely implemented in the treatment of CF patients.
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